Sparks sells regulatory fast pass to Jazz for $110M

Sparks sells regulatory fast pass to Jazz for $110M

Submitted by admin on April 30, 2018 - 9:02pm
Source: 
Biopharma Dive
News Tags: 
Spark Therapeutics
Jazz Pharmaceuticals
priority review vouchers
Headline: 
Sparks sells regulatory fast pass to Jazz for $110M
snippet: 

Spark Therapeutics has sold a priority review voucher (PRV) to Jazz Pharmaceuticals for $110 million, according to a Monday disclosure.

Do Not Allow Advertisers to Use My Personal information